Copyright
©The Author(s) 2021.
World J Clin Cases. Mar 26, 2021; 9(9): 2110-2122
Published online Mar 26, 2021. doi: 10.12998/wjcc.v9.i9.2110
Published online Mar 26, 2021. doi: 10.12998/wjcc.v9.i9.2110
Fentanyl transdermal patch | Buprenorphine transdermal patch | |
Absorption | Bioavailability, 92%; Plasma protein binding, 79%-87%; Cmax, 2.6 μg/L; Effective time, 12.7-16.6 h; Peak time 38.1 h; AUC, 117 μg/L; H (0-72 h) | Bioavailability, 50%; Plasma protein binding, 96%; Cmax, 305 pg/mL; Onset time 21 h; Peak time, about 60 h; AUC, 20228 pg/mL |
Metabolism | Metabolized by CYP3A4 in the liver, and the metabolites are basically inactive | Metabolized by CYP3A4 in the liver |
Elimination | The half-life of the transdermal patch is about 17 h (13-22 h) | The half-life of the transdermal patch is 25.3 h |
Mechanism | μ opioid receptor agonist | μ opioid receptor partial agonist, δ opioid receptor agonist, weak κ opioid receptor antagonist, ORL-1 agonist |
Indication | Moderate to severe chronic pain and intractable pain treated with opioid analgesics | Chronic pain beyond the control of nonopioid analgesics |
Dosage form specification | 2.1-, 4.2-, 8.4- and 12.6-mg paste; Four specifications, lasting for 72 h | 5-, 10- and 20-mg paste. Each paste is used for 7 d |
Adverse reactions, > 10% | Nausea, headache, constipation, dry mouth, drowsiness, fuzzy consciousness, powerlessness, sweating | Erythema, pruritus, nausea |
- Citation: Ma K, Jiang W, Wang YX, Wang L, Lv Y, Liu JF, Liu RG, Liu H, Xiao LZ, Du DP, Lu LJ, Yang XQ, Xia LJ, Huang D, Fu ZJ, Peng BG, Liu YQ. Expert consensus of the Chinese Association for the Study of Pain on pain treatment with the transdermal patch. World J Clin Cases 2021; 9(9): 2110-2122
- URL: https://www.wjgnet.com/2307-8960/full/v9/i9/2110.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i9.2110